Clinical trial · Observational
Breast Cancer Self-Efficacy Scale for Partners
Developing the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): PI no longer working at Indiana University;
Summary
Brief summary (as posted)
The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical, psychological, social and overall QoL in partners as well. However, this hypothesis has yet to be tested, in part because no scale exists to measure cancer-related self-efficacy in partners. Development and psychometric testing of such a scale is a critical first step in developing a theoretical model predicting QoL in this population. Partners of BCS often report lower QoL compared to partners of healthy women, making them an important focus of research. During the award period, the applicant will follow standard instrument development procedures to develop the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P) and test the scale's psychometric properties using a large and diverse sample of partners of breast cancer survivors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Partners of breast cancer survivors
- description
- Convenience sample of partners/significant others/spouses of breast cancer survivors
Primary outcomes (1)
- measure
- Fear of Cancer Progression and Recurrence (FCR7)
- timeFrame
- Day 1
- description
- 7-item scale assessing concerns that the cancer will progress or return, previously tested in samples of breast cancer survivor caregivers/spouses, Cronbach alpha=.91.
Secondary outcomes (1)
- measure
- PROMIS Depression Short Form (8 items)
- timeFrame
- Day 1
- description
- 8-item scale assessing depressive symptoms. PROMIS measures were developed using sophisticated techniques and tested with over 21,000 people, including cancer patients. Cronbach alpha=.92.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Identifies as a partner, significant other, or spouse of an individual diagnosed with non-metastatic breast cancer * Is 18 years of age or over * Is able and willing to attend a focus group, individual interview, or complete an online survey * Is able to access the internet * Is able to carry on normal everyday conversation Exclusion Criteria: · Partners who have separated or divorced since survivors' diagnosis
References
Publications (0)
Data not yet available